Abstracts tagged "gout"

Abstract Number: 2241 • 2015 ACR/ARHP Annual Meeting
Treating to Target in Gout: The Epidemiology of Serum Urate Measurement Among Patients with Incident Gout in Usual Care Settings in the United States
Marsha Raebel¹, Liza Reifler¹, David Tabano¹, Kristin Goddard¹, Andrew Sterrett¹, T Craig Cheetham², Leslie Harrold³, Daniel Sapp⁴, Mark Schmidt⁴, Javier Nuevo⁵, Robert Morlock⁶ and Gregory Nichols⁴, ¹Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, ²Kaiser Permanente Southern California, Pasadena, CA, ³Dept of Medicine, UMass Medical School, Worcester, MA, ⁴Center for Health Research, Kaiser Permanente Northwest, Portland, OR, ⁵AstraZeneca, Madrid, Spain, Madrid, Spain, ⁶Ardea Bioscience, San Diego, CA
Background/Purpose: American College of Rheumatology (ACR) guidelines recommend lowering serum urate (sUA) to a target value in patients with gout to prevent crystal deposition/promote crystal…
Abstract Number: 241 • 2015 ACR/ARHP Annual Meeting
Inflammatory Syndrome in Polyarticular Gout – Description of a Previously Neglected Entity
Valentin S. Schäfer¹, Andreas Krause² and Wolfgang A. Schmidt², ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: Inflammatory polyarticular gout occurs in clinical practice. However, only very few single case reports have been published as yet. This case series aims at…
Abstract Number: 2242 • 2015 ACR/ARHP Annual Meeting
Compliance with Allopurinol Among Hypertensive Patients with Gout Diagnosis and the Relationship to Onset of End-Stage Renal Disease
Sylvie Perreault¹, Javier Nuevo², Scott Baumgartner³ and Robert Morlock⁴, ¹University of Montreal, Montreal, QC, Canada, ²AstraZeneca, Madrid, Spain, Madrid, Spain, ³Ardea Biosciences, Inc., San Diego, CA, ⁴4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: The risk of end-stage renal disease (ESRD) in both hypertension and gout has been examined in the clinical literature. However, the impact of allopurinol…
Abstract Number: 924 • 2015 ACR/ARHP Annual Meeting
Patient and Provider Factors in Optimal Gout Management
Brian Coburn¹, Kayli Bendlin², Harlan Sayles¹ and Ted R. Mikuls¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Pharmacy Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE
Background/Purpose: Gout is the most common inflammatory arthritis worldwide. Despite its prevalence and the availability of effective therapies, studies have consistently characterized gout quality of…
Abstract Number: 2243 • 2015 ACR/ARHP Annual Meeting
Economic Burden of Controlled Gout, Uncontrolled Gout, and Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Robert Morlock¹, Natalia M. Flores², Kathy Annunziata³, Jonathan Chapnick⁴ and Javier Nuevo⁵, ¹4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ²Kantar Health, Foster City, CA, ³Kantar Health, Princeton, NJ, ⁴Kantar Health, Horsham, PA, ⁵AstraZeneca, Madrid, Spain, Madrid, Spain
Background/Purpose: Gout is one of the most common forms of inflammatory arthritis and is caused by chronic high serum uric acid (sUA) levels (ie, hyperuricemia),…
Abstract Number: 1334 • 2015 ACR/ARHP Annual Meeting
Bone Erosion in Gout: Relationship with Tophus Urate and Soft Tissue Volumes. a Conventional and Dual Energy CT Study
Mark Sapsford¹, Gregory Gamble², Opetaia Aati², Julie Knight¹, Anne Horne², Anthony Doyle¹ and Nicola Dalbeth², ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Imaging and pathology studies have established the close relationship between intraosseous tophus and bone erosion in gout. The tophus is an organised structure consisting…
Abstract Number: 2244 • 2015 ACR/ARHP Annual Meeting
Risk of Incident Atrial Fibrillation in Gout
Seoyoung C. Kim¹, Jun Liu² and Daniel H. Solomon³, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Atrial fibrillation (AF) is the most common arrhythmia associated with cardiovascular disease and mortality. There are increasing data supporting the role of inflammation in…
Abstract Number: 1165 • 2014 ACR/ARHP Annual Meeting
Evaluation of Symptom Control Among Treated Gout Patients in the United States, United Kingdom, and Germany
Robert Morlock¹, Chris Storgard², Vernon F. Schabert³, Augustina Ogbonnaya³, Pierre Chevalier⁴, Dionne Hines³ and Sulabha Ramachandran⁵, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²Ardea Biosciences, Inc., San Diego, CA, ³IMS Health, Alexandria, VA, ⁴IMS Health, Vilvoorde, Belgium, ⁵AstraZeneca, Wilmington, DE
Background/Purpose: Gout affects approximately 1-4% of the population in developed Western countries. The hallmark signs of gout are elevated serum uric acid (SUA) level, episodes…
Abstract Number: 105 • 2014 ACR/ARHP Annual Meeting
Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Robert Morlock¹, Natalia M. Flores², Kathy Annunziata³, J. Chapnick⁴ and Sulabha Ramachandran⁵, ¹4939 Directors Place, Ardea Biosciences, San Diego, CA, ²Kantar Health, Foster City, CA, ³Kantar Health, Princeton, NJ, ⁴Kantar Health, Horsham, PA, ⁵AstraZeneca, Wilmington, DE
Background/Purpose: Gout is caused by chronic high serum uric acid (SUA) levels (i.e., hyperuricemia), which leads to the deposition of monosodium urate crystals in musculoskeletal…
Abstract Number: 888 • 2014 ACR/ARHP Annual Meeting
Annual Medical Care Expenditures Among US Adults with Gout, 2005 – 2011
Miriam G. Cisternas¹, Louise Murphy², David J. Pasta³, Edward H. Yelin⁴ and Charles Helmick⁵, ¹MGC Data Services, Carlsbad, CA, ²Division of Population Health, Centers for Disease Control and Prevention, Atlanta, GA, ³DMA Corporation, Palo Alto, CA, ⁴Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁵Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Costs associated with gout are of growing interest due to its increasing prevalence, but quantifying those costs has been hampered by its co-occurrence with…
Abstract Number: 827 • 2014 ACR/ARHP Annual Meeting
Gout and the Risk of Alzheimer’s Disease: A Population-Based Cohort Study
Na Lu¹, Yuqing Zhang¹, Alberto Ascherio², Miguel Hernan², Tuhina Neogi¹, Maureen Dubreuil^3,4 and Hyon K. Choi⁵, ¹Boston University School of Medicine, Boston, MA, ²Epidemiology, Harvard School of Public Health, Boston, MA, ³Rheumatology, Boston University Medical Center, Boston, MA, ⁴Rheumatology, Boston VA HealthCare System, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: While gout is associated with cardiovascular (CV)-metabolic comorbidities and their sequelae, uric acid's anti-oxidant effects may have neuroprotective benefits. Several studies have found an…
Abstract Number: 250 • 2014 ACR/ARHP Annual Meeting
Early Gout Pain Response at 28 Hours Predicts Response at 5 Days on Both Patient Pain and Physician Global Assessment
Paul M. Peloso¹, Ted R. Mikuls², Brian W. Coburn³, H. Ralph Schumacher Jr.⁴, Davis F. Gates¹, Zoran Popmihajlov¹, Walter L. Straus¹ and R. Andrew Moore⁵, ¹Merck & Co., Inc., Whitehouse Station, NJ, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Omaha VA and University of Nebraska Medical Center, Omaha, NE, USA, Omaha, NE, ⁴Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵University of Oxford, Nuffield Division of Anaesthetics, Oxford, England
Background/Purpose This post-hoc analysis from a randomized trial1in acute gout asked whether early pain responses predict subsequent pain and investigator global responses. Methods Patient assessment…
Abstract Number: 180 • 2014 ACR/ARHP Annual Meeting
Analytical Comparison Between Point of Care Uric Acid Testing Meters
Jonathan Paraskos¹, Zsofia Berke², Jason Cook¹, Jeffrey N. Miner³, Martin Braddock¹, Adam Platt¹ and Glen Hughes¹, ¹AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ²R&D, AstraZeneca, Mölndal, Sweden, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout is a chronic, painful, debilitating form of arthritis resulting from elevated levels of serum uric acid (SUA), termed hyperuricemia. Hyperuricemia is caused by…
Abstract Number: 171 • 2014 ACR/ARHP Annual Meeting
High-Protein Diet (Atkins Diet) and Uric Acid Response
Na Lu¹, Iris Shai², Yuqing Zhang¹, Gary Curhan³ and Hyon K. Choi⁴, ¹Boston University School of Medicine, Boston, MA, ²Harvard School of Public Health, Boston, MA, ³German Research Center for Environmental Health, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose The conventional low-purine dietary approach to gout offers limited efficacy, palatability, and sustainability, and promotes increased consumption of refined carbohydrates and saturated fat that…
Abstract Number: 169 • 2014 ACR/ARHP Annual Meeting
Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Jasvinder A. Singh¹, Rekha Ramachandaran², Jie Zhang³, Fenglong Xie⁴, Shuo Yang⁵, Huifeng Yun⁶ and Jeffrey R. Curtis², ¹Department of Medicine, University of Alabama, Tuscaloosa, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Diabetes is a well-recognized risk factor for heart disease, increasing the risk of heart disease by 2-3 fold in many studies. Recent ACC/AHA lipid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].